Sector: MedicalUnited Therapeutics Corporation (NASDAQ: UTHR)
Ranking History
Scan Date: | 11/10/2009 |
Sector: | Medical |
Funamental : | 14 |
Technical : | 11 |
Performance : | 234 |
Overall: | 39 |
Number of Stocks: | 306 |
Scan Date: | 11/3/2009 |
Sector: | Medical |
Funamental : | 15 |
Technical : | 16 |
Performance : | 251 |
Overall: | 51 |
Number of Stocks: | 306 |
Scan Date: | 10/27/2009 |
Sector: | Medical |
Funamental : | 261 |
Technical : | 37 |
Performance : | 271 |
Overall: | 231 |
Number of Stocks: | 306 |
Headlines
- United Therapeutics Corporation Reports Third Quarter 2009 Financial Results
Oct 29, 2009 07:02 AM | UTHR
- United Therapeutics Corporation to Announce Third Quarter 2009 Financial Results Before Market Open on Thursday, October 29, 2009
Oct 22, 2009 07:01 AM | UTHR
- 2010 NC Quality in Biopharma Conference to be hosted at NC State University's BTEC
Oct 21, 2009 11:00 AM | UTHR
- Quarterly Changes to the NASDAQ Q-50 Index
Sep 11, 2009 08:06 PM | BUCY, DWA, GMCR, LINE, MCRS, NDAQ
- United Therapeutics Corporation Announces Stock Split To Be Effected as a Stock Dividend
Sep 01, 2009 04:01 PM | UTHR
- Bullish Picks for Next Week
Aug 01, 2009 01:04 PM | BMRN, CVGW, MSPD, NVEC, RADS, UTHR
- MIGENIX Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Jul 10, 2009 08:32 AM | CADX, MGI, UTHR
- Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline
Jun 19, 2009 12:50 PM | AGN, ALXN, BMRN, PDLI, REGN, SPPI
- BioMedReports FDA Calendar: 19 Hot Summer Trades
Jun 17, 2009 08:18 AM | ACUR, AEZS, ALTH, AMAG, AUXL, DDSS
- FDA, Clinical Trial Updates: MAPP, CYTK, and HEB Post Big Gains
May 27, 2009 08:31 AM | ALTH, AMGN, BMY, CYTK, ICAD, MAPP
- Licensing Executives Society Announces 2009 Deals of Distinction Awards
Oct 21, 2009 03:52 PM | AGN, LLY, UTHR
- United Therapeutics Corporation Reports Second Quarter 2009 Financial Results
Jul 31, 2009 06:50 AM | LLY, UTHR
- FDA Approves TYVASO (Treprostinil) Inhalation Solution for the Treatment of Pulmonary Arterial Hypertension
Jul 30, 2009 01:07 PM | UTHR
- United Therapeutics Corporation to Announce Second Quarter 2009 Financial Results Before Market Open on Friday, July 31, 2009
Jul 24, 2009 07:01 AM | UTHR
- United Therapeutics Corporation (UTHR) Chairman and Chief Executive Officer to Ring the NASDAQ Stock Market Opening Bell
Jun 16, 2009 06:17 PM | NDAQ, UTHR
- Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily
Jun 09, 2009 07:01 AM | LLY, UTHR
- FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
May 26, 2009 05:22 AM | UTHR
- United Therapeutics Reports First Quarter 2009 Financial Results
May 01, 2009 07:53 AM | UTHR
- Richard Giltner Joins United Therapeutics Board of Directors
Apr 29, 2009 04:30 PM | UTHR
- U.S. Food and Drug Administration Extends Action Date for Inhaled Treprostinil (Tyvaso) New Drug Application by Three Months
Apr 28, 2009 05:41 PM | UTHR
- Form 4 UNITED THERAPEUTICS CORP For: Nov 20 Filed by: MAHON PAUL A (10K)
Nov 20, 2009 05:52 PM
- Form 4 MAHON PAUL A For: Oct 15 (10K)
Oct 15, 2009 05:52 PM
- Form 4 JEFFS ROGER For: Oct 15 (10K)
Oct 15, 2009 05:48 PM
- Form 4 MAHON PAUL A For: Oct 01 (10K)
Oct 01, 2009 07:49 PM
- Form 4 JEFFS ROGER For: Oct 01 (10K)
Oct 01, 2009 07:46 PM
- Form 4 PATUSKY CHRISTOPHER For: Oct 01 (10K)
Oct 01, 2009 07:43 PM
- Form 4 CAUSEY CHRISTOPHER For: Oct 01 (10K)
Oct 01, 2009 07:39 PM
- Form 4 MAHON PAUL A For: Sep 24 (10K)
Sep 25, 2009 04:15 PM
- Form 4 CAUSEY CHRISTOPHER For: Sep 23 (10K)
Sep 23, 2009 02:42 PM
- Form 4 PATUSKY CHRISTOPHER For: Sep 03 (10K)
Sep 03, 2009 05:59 PM
Analyst Ratings
Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
Share Performance
|
Period
|
UTHR
|
Compare to S&P
|
| YTD |
43.60 %
|
18.84 %
|
| 4 Weeks |
5.47 %
|
4.33 %
|
| 12 Weeks |
-2.50 %
|
-8.08 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: 566.67 %
|
|
EPS Growth in Last Year: -16.00 %
|
|
Sales Growth in Last Quarter: 15.76 %
|
|
Sales Growth in Last Quarter: 29.56 %
|
|
